Keros Therapeutics Enters Licensing Agreement and Strategic Partnership with Hansoh Pharma for Rights to Cytopenia Therapy

Keros Therapeutics said it entered into a licensing agreement with Hansoh Healthtech, a subsidiary of Hansoh Pharmaceutical Group in China that will give Hansoh an exclusive license from Keros to develop, manufacture, and commercialize KER-050 within the territories of mainland China, Hong Kong, and Macau.

Photo: Jasbir Seehra, president and CEO of Keros

Under the terms of the agreement, Hansoh is responsible for the development, regulatory approval, and commercialization of KER-050 in mainland China, Hong Kong, and Macau. Keros will receive a $20 million upfront payment and will also be eligible to receive up to $170.5 million in development and commercial milestones, plus tiered royalties on net product sales ranging from the low double digit to high teens.

KER-050 is an experimental therapy being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis.

KER-050 is an engineered ligand trap comprised of a modified ligand-binding domain of the Transforming Growth Factor-Beta receptor known as activin receptor type IIA that is fused to the portion of the human antibody known as the Fc domain.

“This agreement enables us to strategically expand our program, subsidized by non-dilutive capital, while also gaining access to one of the largest pharmaceutical markets globally,” said Jasbir Seehra, president and CEO of Keros.

Author: Rare Daily Staff